0 CHECKOUT

Partial Seizure - Pipeline Review, H1 2015

  • ID: 3280659
  • May 2015
  • 89 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.
  • MORE

Partial Seizure - Pipeline Review, H1 2015

Summary

This, ‘Partial Seizure - Pipeline Review, H1 2015’, provides an overview of the Partial Seizure’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Partial Seizure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Partial Seizure and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eisai Co., Ltd.
  • Novartis AG
  • Pfizer Inc.
  • UCB S.A.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Partial Seizure Overview
Therapeutics Development
Pipeline Products for Partial Seizure - Overview
Pipeline Products for Partial Seizure - Comparative Analysis
Partial Seizure - Therapeutics under Development by Companies
Partial Seizure - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Partial Seizure - Products under Development by Companies
Partial Seizure - Companies Involved in Therapeutics Development
Catalyst Pharmaceutical Partners, Inc.
Eisai Co., Ltd.
Marinus Pharmaceuticals, Inc.
Novartis AG
Pfizer Inc.
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
UCB S.A.
Partial Seizure - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
brivaracetam - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
everolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ganaxolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lacosamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MB-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
perampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pregabalin CR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
selurampanel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SF-0034 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
YKP-3089 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Partial Seizure - Recent Pipeline Updates
Partial Seizure - Dormant Projects
Partial Seizure - Discontinued Products
Partial Seizure - Product Development Milestones
Featured News & Press Releases
Apr 20, 2015: Important UCB presents data on VIMPAT at the 2015 American Academy of Neurology Meeting
Jan 05, 2015: Phase III Trial Of Antiepileptic Drug Perampanel As Adjunctive Therapy In Patients With Refractory Partial-Onset Seizures Conducted In Asia Including Japan And China Meets Primary Endpoint
Dec 08, 2014: UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy
Apr 25, 2014: Eisai Presents Research on FYCOMPA (perampanel) CIII at The American Academy of Neurology's 66th Annual Meeting
Feb 10, 2014: Fycompa to be Resubmitted Early to German Federal Joint Committee for Additional Benefit Assessment
Jan 06, 2014: Eisai Announces Launch of Antiepileptic Drug Fycompa in U.S.
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA (perampanel) CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Jan 02, 2014: Eisai Announces U.S. Availability of FYCOMPA CIII an Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy Age 12 and Older
Nov 20, 2013: New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society
Jul 15, 2013: Mylan Confirms First-to-File Patent Challenge Relating to Vimpat
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Partial Seizure, H1 2015
Number of Products under Development for Partial Seizure - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Partial Seizure - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2015
Partial Seizure - Pipeline by Eisai Co., Ltd., H1 2015
Partial Seizure - Pipeline by Marinus Pharmaceuticals, Inc., H1 2015
Partial Seizure - Pipeline by Novartis AG, H1 2015
Partial Seizure - Pipeline by Pfizer Inc., H1 2015
Partial Seizure - Pipeline by SciFluor Life Sciences, LLC, H1 2015
Partial Seizure - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015
Partial Seizure - Pipeline by UCB S.A., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Partial Seizure Therapeutics - Recent Pipeline Updates, H1 2015
Partial Seizure - Dormant Projects, H1 2015
Partial Seizure - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Partial Seizure, H1 2015
Number of Products under Development for Partial Seizure - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

- Catalyst Pharmaceutical Partners, Inc.
- Eisai Co., Ltd.
- Marinus Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- SciFluor Life Sciences, LLC
- SK Biopharmaceuticals Co., Ltd.
- UCB S.A.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Cache

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.